Cytokinetics (CYTK) Capital Expenditures (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Capital Expenditures of $5.9 million for Q1 2026, up 4.7% year-over-year from $5.7 million in Q1 2025, and down 73.9% quarter-over-quarter from $22.7 million in Q4 2025.
Cytokinetics (CYTK) Capital Expenditures (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Capital Expenditures for 17 consecutive years, with $5.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 4.7% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $25.1 million (up 178.31% YoY), while the FY2025 annual figure was $24.8 million, up 641.61% from the prior year.
- Capital Expenditures declined to $5.9 million in Q1 2026 per CYTK's latest filing, from $22.7 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $22.7 million in Q4 2025 and bottomed at -$2.8 million in Q2 2025.
- Historically, Capital Expenditures has averaged $2.8 million across 5 years, with a median of $899500.0 in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 688.03% in 2025 and fell as far as 4267.65% in 2025.
- Cytokinetics' Capital Expenditures stood at $3.2 million in 2022, then tumbled by 141.78% to -$1.3 million in 2023, then surged by 315.31% to $2.9 million in 2024, then jumped by 688.03% to $22.7 million in 2025, then slumped by 73.9% to $5.9 million in 2026.
- Business Quant data shows CYTK's Capital Expenditures at $5.9 million in Q1 2026, $22.7 million in Q4 2025, and -$742000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 4.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.33 Mn |
| Jun 30, 2026 | 4.33 Mn |
| Mar 31, 2026 | 5.93 Mn |
| Mar 31, 2026 | 5.93 Mn |
| Dec 31, 2025 | 22.72 Mn |
| Dec 31, 2025 | 22.72 Mn |
| Sep 30, 2025 | -742,000.00 |
| Sep 30, 2025 | -742,000.00 |
| Jun 30, 2025 | -2.83 Mn |
| Jun 30, 2025 | -2.83 Mn |
| Mar 31, 2025 | 5.66 Mn |
| Mar 31, 2025 | 5.66 Mn |
| Dec 31, 2024 | 2.88 Mn |
| Dec 31, 2024 | 2.88 Mn |
| Sep 30, 2024 | 394,000.00 |
| Sep 30, 2024 | 394,000.00 |
| Jun 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 68,000.00 |
| Dec 31, 2023 | -1.34 Mn |
| Dec 31, 2023 | -1.34 Mn |